Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)

Corsini, Michele M.; Miller, Robert C.; Haddock, Michael G.; Donohue, John H.; Farnell, Michael B.; Nagorney, David M.; Jatoi, Aminah; McWilliams, Robert R.; Kim, George P.; Bhatia, Sumita; Iott, Matthew J.; Gunderson, Leonard L.

doi:10.1200/jco.2007.15.8782

Cited by 241 publications

(170 citation statements)

References 29 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…Conversely, others have argued that patients with node-negative disease benefit most from adjuvant treatment, underscoring a controversy in patient selection 22 . Interestingly, tumour grade was not associated with use of adjuvant treatment in spite of evidence identifying grade as a putative determinant of response to adjuvant treatment 9,34 .…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

“…Those findings might relate to the hypothesis that patients with nodal disease derive the greatest benefit from adjuvant treatment 9,33,34 . Conversely, others have argued that patients with node-negative disease benefit most from adjuvant treatment, underscoring a controversy in patient selection 22 .…”

Section: Discussionmentioning

confidence: 99%

Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A large retrospective study of 466 consecutive patients with PDA who underwent R0 resection (all margins negative by histology) at Mayo Clinic showed a median OS of 25.2 in the patients who received neoadjuvant CRT compared to the median OS of 19.2 months in patients who did not receive neoadjuvant CRT (P= 0.001). Patients who received neoadjuvant CRT had better 5-year OS (28%) than those who had no neoadjuvant CRT (17%) [9]. pCR has been shown to be associated with lower frequencies of local recurrence and better survival in patients with adenocarcinoma of several anatomic sites who received neoadjuvant therapies [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 92%

Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis

Wang¹,

Zhao²

2012

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

In patients with pancreatic ductal adenocarcinoma (PDA) who received neoadjuvant therapy and pancreatectomy, pathologic complete response (pCR) is rarely observed and the prognostic significance of pCR is not clear. In this study, we reported 11 patients with pCR (2.5%) from 442 patients with PDA who received neoadjuvant treatment and pancreatectomy from 1995 to 2010. There were 6 men and 5 women with median age of 61 years. Four patients had either synchronous or prior history of extra-pancreatic cancer. Five patients received neoadjuvant chemotherapy followed by chemoradiation, and 6 received chemoradiation alone. Ten patients had pancreaticoduodenectomy and one had distal pancreatectomy. Scar and chronic pancreatitis consistent with therapy effect were present in all cases (100%). Pancreatic intraepithelial neoplasia 3 (Pan IN3)/carcinoma in situ was present in 5 cases, PanIN1 and PanIN2 in 5 cases. However, no residual invasive carcinoma or lymph node metastasis was identified in all cases. Follow-up information was available in 10 patients. Follow-up time ranges from 6 to 194 months (median, 63 months). During follow-up, three patients died of other causes and one developed a second primary PDA in the tail of pancreas at 84 months after initial pancreaticoduodenectomy and died at 105 months after the initial diagnosis of PDA. The other 6 patients were alive with no evidence of disease. Patients with pCR had better survival than those who had post-therapy stage I or IIA

show abstract

“…More significantly, exogenous expression of PUMA decreased the to any treatments. 18,19 Acquired resistance of pancreatic cancer cells toward 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. 20 There is urgent demand to develop novel therapy strategies to re-establish or enhance the functional apoptosis pathways to improve the efficacy in pancreatic cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA

Wang¹,

Pei²,

Luan³

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)

Abstract: This study represents one of the largest, single-institution, retrospective reviews of adjuvant therapy in patients after R0 resection of carcinoma of the pancreas. Overall survival was better in patients who received adjuvant CT-RT.

Cited by 241 publications

References 29 publications

Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level

Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level

Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis

A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA

Contact Info

Product

Resources

About